S&P 500   2,925.73 (-1.78%)
DOW   25,201.91 (-2.19%)
QQQ   204.52 (-0.54%)
AAPL   270.43 (-1.13%)
FB   188.20 (-0.82%)
MSFT   159.88 (+1.07%)
CGC   18.15 (-1.57%)
NVDA   264.54 (+4.73%)
BABA   202.09 (-1.43%)
MU   52.36 (+3.52%)
AMD   45.36 (+3.07%)
T   34.91 (-2.30%)
ACB   1.37 (-5.54%)
F   6.86 (-1.58%)
NFLX   367.30 (-1.19%)
BAC   28.32 (-2.78%)
GILD   68.90 (-5.17%)
S&P 500   2,925.73 (-1.78%)
DOW   25,201.91 (-2.19%)
QQQ   204.52 (-0.54%)
AAPL   270.43 (-1.13%)
FB   188.20 (-0.82%)
MSFT   159.88 (+1.07%)
CGC   18.15 (-1.57%)
NVDA   264.54 (+4.73%)
BABA   202.09 (-1.43%)
MU   52.36 (+3.52%)
AMD   45.36 (+3.07%)
T   34.91 (-2.30%)
ACB   1.37 (-5.54%)
F   6.86 (-1.58%)
NFLX   367.30 (-1.19%)
BAC   28.32 (-2.78%)
GILD   68.90 (-5.17%)
S&P 500   2,925.73 (-1.78%)
DOW   25,201.91 (-2.19%)
QQQ   204.52 (-0.54%)
AAPL   270.43 (-1.13%)
FB   188.20 (-0.82%)
MSFT   159.88 (+1.07%)
CGC   18.15 (-1.57%)
NVDA   264.54 (+4.73%)
BABA   202.09 (-1.43%)
MU   52.36 (+3.52%)
AMD   45.36 (+3.07%)
T   34.91 (-2.30%)
ACB   1.37 (-5.54%)
F   6.86 (-1.58%)
NFLX   367.30 (-1.19%)
BAC   28.32 (-2.78%)
GILD   68.90 (-5.17%)
S&P 500   2,925.73 (-1.78%)
DOW   25,201.91 (-2.19%)
QQQ   204.52 (-0.54%)
AAPL   270.43 (-1.13%)
FB   188.20 (-0.82%)
MSFT   159.88 (+1.07%)
CGC   18.15 (-1.57%)
NVDA   264.54 (+4.73%)
BABA   202.09 (-1.43%)
MU   52.36 (+3.52%)
AMD   45.36 (+3.07%)
T   34.91 (-2.30%)
ACB   1.37 (-5.54%)
F   6.86 (-1.58%)
NFLX   367.30 (-1.19%)
BAC   28.32 (-2.78%)
GILD   68.90 (-5.17%)
Log in

NASDAQ:EIDX - Eidos Therapeutics Stock Price, Forecast & News

$49.09
+0.09 (+0.18 %)
(As of 02/28/2020 11:40 AM ET)
Today's Range
$47.17
Now: $49.09
$49.09
50-Day Range
$47.18
MA: $53.53
$57.07
52-Week Range
$16.87
Now: $49.09
$66.56
Volume2,115 shs
Average Volume106,843 shs
Market Capitalization$1.84 billion
P/E RatioN/A
Dividend YieldN/A
Beta-0.83
Eidos Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) amyloidosis (ATTR). It is developing AG10, an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR. The company was founded in 2013 and is headquartered in San Francisco, California.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:EIDX
CUSIPN/A
CIKN/A
Phone415-887-1471

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$26.69 million
Book Value$4.22 per share

Profitability

Net Income$-33,290,000.00

Miscellaneous

Employees28
Market Cap$1.84 billion
Next Earnings Date5/5/2020 (Estimated)
OptionableNot Optionable

Receive EIDX News and Ratings via Email

Sign-up to receive the latest news and ratings for EIDX and its competitors with MarketBeat's FREE daily newsletter.


Eidos Therapeutics (NASDAQ:EIDX) Frequently Asked Questions

What is Eidos Therapeutics' stock symbol?

Eidos Therapeutics trades on the NASDAQ under the ticker symbol "EIDX."

How were Eidos Therapeutics' earnings last quarter?

Eidos Therapeutics Inc (NASDAQ:EIDX) posted its quarterly earnings data on Wednesday, February, 26th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.49) by $0.02. View Eidos Therapeutics' Earnings History.

When is Eidos Therapeutics' next earnings date?

Eidos Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, May 5th 2020. View Earnings Estimates for Eidos Therapeutics.

What price target have analysts set for EIDX?

7 brokerages have issued twelve-month price targets for Eidos Therapeutics' stock. Their forecasts range from $45.00 to $80.00. On average, they expect Eidos Therapeutics' share price to reach $61.29 in the next year. This suggests a possible upside of 24.8% from the stock's current price. View Analyst Price Targets for Eidos Therapeutics.

What is the consensus analysts' recommendation for Eidos Therapeutics?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eidos Therapeutics in the last year. There are currently 1 sell rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Eidos Therapeutics.

Has Eidos Therapeutics been receiving favorable news coverage?

Headlines about EIDX stock have been trending extremely negative recently, InfoTrie reports. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Eidos Therapeutics earned a coverage optimism score of -4.4 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for Eidos Therapeutics.

Are investors shorting Eidos Therapeutics?

Eidos Therapeutics saw a decline in short interest in February. As of February 14th, there was short interest totalling 2,340,000 shares, a decline of 7.9% from the January 30th total of 2,540,000 shares. Based on an average daily trading volume, of 156,400 shares, the short-interest ratio is currently 15.0 days. Approximately 19.4% of the company's shares are sold short. View Eidos Therapeutics' Current Options Chain.

Who are some of Eidos Therapeutics' key competitors?

What other stocks do shareholders of Eidos Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Eidos Therapeutics investors own include Exelixis (EXEL), Crispr Therapeutics (CRSP), Micron Technology (MU), Roku (ROKU), Aduro BioTech (ADRO), Agile Therapeutics (AGRX), Global Blood Therapeutics (GBT), NVIDIA (NVDA), DexCom (DXCM) and ImmunoGen (IMGN).

Who are Eidos Therapeutics' key executives?

Eidos Therapeutics' management team includes the folowing people:
  • Dr. Neil Kumar, CEO & Director (Age 40)
  • Dr. Isabella Graef M.D., Founder & Board Advisor (Age 54)
  • Dr. Uma Sinha, Chief Scientific Officer (Age 62)
  • Dr. Cameron Turtle, Chief Bus. Officer (Age 29)
  • Dr. Hoyoung Huh, Consultant (Age 50)

When did Eidos Therapeutics IPO?

(EIDX) raised $101 million in an initial public offering on Wednesday, June 20th 2018. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and BofA Merrill Lynch acted as the underwriters for the IPO and Barclays was co-manager.

Who are Eidos Therapeutics' major shareholders?

Eidos Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Perceptive Advisors LLC (1.86%), FMR LLC (1.10%), Lord Abbett & CO. LLC (0.96%), Artisan Partners Limited Partnership (0.90%), Driehaus Capital Management LLC (0.58%) and State Street Corp (0.58%). Company insiders that own Eidos Therapeutics stock include Bridgebio Pharma Llc, Bridgebio Pharma, Inc, Cameron Turtle, Christine Siu, Eric Aguiar, Jonathan C Fox, Neil Kumar, Rajeev M Shah and Uma Sinha. View Institutional Ownership Trends for Eidos Therapeutics.

Which institutional investors are selling Eidos Therapeutics stock?

EIDX stock was sold by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, Victory Capital Management Inc., Victory Capital Management Inc., Schonfeld Strategic Advisors LLC, Candriam Luxembourg S.C.A., Fiera Capital Corp, SG Americas Securities LLC and EAM Global Investors LLC. Company insiders that have sold Eidos Therapeutics company stock in the last year include Cameron Turtle, Christine Siu, Jonathan C Fox and Uma Sinha. View Insider Buying and Selling for Eidos Therapeutics.

Which institutional investors are buying Eidos Therapeutics stock?

EIDX stock was acquired by a variety of institutional investors in the last quarter, including Artisan Partners Limited Partnership, Driehaus Capital Management LLC, Parkman Healthcare Partners LLC, FMR LLC, Sei Investments Co., EAM Investors LLC, Point72 Asset Management L.P. and Goldman Sachs Group Inc.. Company insiders that have bought Eidos Therapeutics stock in the last two years include Bridgebio Pharma Llc, Bridgebio Pharma, Inc, Eric Aguiar, Neil Kumar and Rajeev M Shah. View Insider Buying and Selling for Eidos Therapeutics.

How do I buy shares of Eidos Therapeutics?

Shares of EIDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Eidos Therapeutics' stock price today?

One share of EIDX stock can currently be purchased for approximately $49.09.

How big of a company is Eidos Therapeutics?

Eidos Therapeutics has a market capitalization of $1.84 billion and generates $26.69 million in revenue each year. The company earns $-33,290,000.00 in net income (profit) each year or ($1.03) on an earnings per share basis. Eidos Therapeutics employs 28 workers across the globe.View Additional Information About Eidos Therapeutics.

What is Eidos Therapeutics' official website?

The official website for Eidos Therapeutics is http://www.eidostx.com/.

How can I contact Eidos Therapeutics?

Eidos Therapeutics' mailing address is 101 MONTGOMERY STREET SUITE 2550, SAN FRANCISCO CA, 94104. The company can be reached via phone at 415-887-1471 or via email at [email protected]


MarketBeat Community Rating for Eidos Therapeutics (NASDAQ EIDX)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  127 (Vote Outperform)
Underperform Votes:  139 (Vote Underperform)
Total Votes:  266
MarketBeat's community ratings are surveys of what our community members think about Eidos Therapeutics and other stocks. Vote "Outperform" if you believe EIDX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EIDX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/28/2020 by MarketBeat.com Staff

Featured Article: Most Volatile Stocks

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel